Patient characteristics are summarized in Table 1. The median age was 69 (range, 47–86) years. The median follow-up duration was 41.8 (range, 14.1–59.9) months. Among 293 patients, 9, 101, and 183 patients were classified as having low, intermediate, and high risks, respectively. The Median PV and IPP were 26.2 (range, 8.1–101.3) mL and 0 (range 0–12) mm in 293 patients, and the median TZV was 9.2 (range, 1.6–48.4) mL in 278 patients. Table 2 shows the maximal acute and late urinary toxicities in this study. Among acute urinary toxicities, urinary frequency was the major symptom observed. Grades 1 and 2 urinary frequency were observed in 36 (12.3%) and 11 (3.8%) patients, respectively. The number of patients with any acute urinary toxicities was 54 (18.4%) for grade 1, 14 (4.8%) for grade 2, and 0 for grade 3. Similarly, the number of patients with any late urinary toxicities, except for hematuria, was 46 (15.7%) for grade 1, 42 (14.3%) for grade 2, and 0 for grade 3. Grade 1, 2 and 3 hematuria were observed in 17, 1 and 3 patients, respectively. The presence or absence of IPP was significantly different between Grade 0 and Grade 1 and 2 for acute urinary toxicities, with odds ratios and relative risk of 2.364 and 1.866, respectively (P < 0.01). Additionally, IPP was significantly different between Grade 0 and 1 and Grade 2 for late urinary toxicities, with odds ratios and relative risk of 2.350 and 2.028, respectively (P < 0.05). PV or TZV was not significantly associated with urinary toxicities and none of these parameters were associated with hematuria.